|Recombinant Mouse Cystatin-E / CST6 / Cystatin-M / Cystatin-6 protein (Catalog#50916-M08H)|
|0.2 μm filtered solution in PBS|
|Produced in rabbits immunized with purified, recombinant Mouse Cystatin-E / CST6 / Cystatin-M / Cystatin-6 (rM Cystatin-E / CST6 / Cystatin-M / Cystatin-6; Catalog#50916-M08H; NP_082899.1; Met1-Ala152). Cystatin-E / CST6 / Cystatin-M / Cystatin-6 specific IgG was purified by Mouse Cystatin-E / CST6 / Cystatin-M / Cystatin-6 affinity chromatography.|
ELISA: 0.1-0.2 μg/mL
This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Mouse Cystatin-E / CST6 / Cystatin-M / Cystatin-6. The detection limit for Mouse Cystatin-E / CST6 / Cystatin-M / Cystatin-6 is approximately 0.00975 ng/well.
IHC-P: 0.1-2 μg/mL
Cystatin E/M, also referred to as CST6, is a member of type 2 cysteine proteinase inhibitors of the cystatin superfamily, and inhibits papain and cathepsin B. Cystatin E is a low molecular mass secreted protein existing in both a glycosylated (17 kDa) and an unglycosylated (14 kDa) form, with two characteristic intrachain disulfide bridges. Expression of cystatin M/E is found to be restricted to the epidermis, more specifically in the stratum granulosum, sweat glands, sebaceous glands, and the hair follicles. In addition to its function as a cysteine protease inhibitor, cystatin M/E also serves as a target for cross-linking by transglutaminases. Accordingly, cystatin M/E was suggested to be involved in barrier formation and maintenance. Furthermore, studies have revealed that cystatin M/E is frequently epigenetically inactivated during breast carcinogenesis, and thus be regarded as a candidate of tumour suppressor gene.